| [1] |
TARGHER G, BYRNE CD, TILG H. MASLD: A systemic metabolic disorder with cardiovascular and malignant complications[J]. Gut, 2024, 73( 4): 691- 702. DOI: 10.1136/gutjnl-2023-330595. |
| [2] |
MIAO L, TARGHER G, BYRNE CD, et al. Current status and future trends of the global burden of MASLD[J]. Trends Endocrinol Metab, 2024, 35( 8): 697- 707. DOI: 10.1016/j.tem.2024.02.007. |
| [3] |
YIP TCF, FAN JG, WONG VWS. China’s fatty liver crisis: A looming public health emergency[J]. Gastroenterology, 2023, 165( 4): 825- 827. DOI: 10.1053/j.gastro.2023.06.008. |
| [4] |
DIEHL AM, DAY C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med, 2017, 377( 21): 2063- 2072. DOI: 10.1056/NEJMra1503519. |
| [5] |
RINELLA ME, NEUSCHWANDER-TETRI BA, SIDDIQUI MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77( 5): 1797- 1835. DOI: 10.1097/HEP.0000000000000323. |
| [6] |
KOKKORAKIS M, BOUTARI C, HILL MA, et al. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges[J]. Metabolism, 2024, 154: 155835. DOI: 10.1016/j.metabol.2024.155835. |
| [7] |
TAUB R, CHIANG E, CHABOT-BLANCHET M, et al. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist[J]. Atherosclerosis, 2013, 230( 2): 373- 380. DOI: 10.1016/j.atherosclerosis.2013.07.056. |
| [8] |
HARRISON SA, BASHIR MR, GUY CD, et al. Resmetirom(MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2019, 394( 10213): 2012- 2024. DOI: 10.1016/S0140-6736(19)32517-6. |
| [9] |
HARRISON SA, RATZIU V, ANSTEE QM, et al. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2024, 59( 1): 51- 63. DOI: 10.1111/apt.17734. |
| [10] |
HARRISON SA, BEDOSSA P, GUY CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024, 390( 6): 497- 509. DOI: 10.1056/NEJMoa2309000. |
| [11] |
HARRISON SA, TAUB R, NEFF GW, et al. Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial[J]. Nat Med, 2023, 29( 11): 2919- 2928. DOI: 10.1038/s41591-023-02603-1. |
| [12] |
ClinicalTrials. gov. phaseA 3 study to evaluate safety and biomarkers of Resmetirom(MGL-3196) in patients with non-alcoholic fatty liver disease(NAFLD), MAESTRO-NAFLD-open-label-extension(MAESTRO-NAFLD-OLE)[EB/OL].( 2023-12-04)[ 2024-04-16]. https://clinicaltrials.gov/study/NCT04951219?term=NCT04951219&rank=1. https://clinicaltrials.gov/study/NCT04951219?term=NCT04951219&rank=1 |
| [13] |
ClinicalTrials. gov. A phase 3 study to evaluate the effect of Resmetirom on clinical outcomes in patients with well-compensated NASH cirrhosis(MAESTRO-NASH-OUTCOMES)[EB/OL].( 2024-03-25)[ 2024-04-16]. https://clinicaltrials.gov/study/NCT05500222?term=NCT05500222&rank=1. https://clinicaltrials.gov/study/NCT05500222?term=NCT05500222&rank=1 |
| [14] |
LEUNG PB, DAVIS AM, KUMAR S. Diagnosis and management of nonalcoholic fatty liver disease[J]. JAMA, 2023, 330( 17): 1687- 1688. DOI: 10.1001/jama.2023.17935. |
| [15] |
ANGULO P, KLEINER DE, DAM-LARSEN S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2015, 149( 2): 389- 397. DOI: 10.1053/j.gastro.2015.04.043. |
| [16] |
YOUNOSSI ZM, RATZIU V, LOOMBA R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2019, 394( 10215): 2184- 2196. DOI: 10.1016/S0140-6736(19)33041-7. |
| [17] |
ESLAM M, ALVANI R, SHIHA G. Obeticholic acid: Towards first approval for NASH[J]. Lancet, 2019, 394( 10215): 2131- 2133. DOI: 10.1016/S0140-6736(19)32963-0. |
| [18] |
LUO L, ZOU H, ZHENG S, et al. Letter to the editor: Suggestions for rational management of nonalcoholic fatty liver disease[J]. Hepatology, 2019, 70( 4): 1492- 1493. DOI: 10.1002/hep.30797. |
| [19] |
HARRISON SA, FRIAS JP, NEFF G, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis(HARMONY): A multicentre, randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Gastroenterol Hepatol, 2023, 8( 12): 1080- 1093. DOI: 10.1016/S2468-1253(23)00272-8. |
| [20] |
LOOMBA R, SANYAL AJ, KOWDLEY KV, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH[J]. N Engl J Med, 2023, 389( 11): 998- 1008. DOI: 10.1056/NEJMoa2304286. |
| [21] |
NEWSOME PN, BUCHHOLTZ K, CUSI K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384( 12): 1113- 1124. DOI: 10.1056/NEJMoa2028395. |
| [22] |
VIOLI F, CANGEMI R. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 363( 12): 1185- 1186. DOI: 10.1056/NEJMc1006581. |
| [23] |
The Lancet Gastroenterology Hepatology. Resmetirom for NASH: Balancing promise and prudence[J]. Lancet Gastroenterol Hepatol, 2024, 9( 4): 273. DOI: 10.1016/S2468-1253(24)00049-9. |
| [24] |
CUSI K. Selective agonists of thyroid hormone receptor beta for the treatment of NASH[J]. N Engl J Med, 2024, 390( 6): 559- 561. DOI: 10.1056/NEJMe2314365. |
| [25] |
PETTA S, TARGHER G, ROMEO S, et al. The first MASH drug therapy on the horizon: Current perspectives of resmetirom[J]. Liver Int, 2024, 44( 7): 1526- 1536. DOI: 10.1111/liv.15930. |
DownLoad:
